Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease

Parkinsonism and Related Disorders

Volumn 20, Issue SUPPL.1, 2014, Pages

  Youdim, Moussa B H ^a   Kupershmidt, Lana ^a   Amit, Tamar ^a   Weinreb, Orly ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

BDNF; GDNF; Iron chelator; Ladostigil; Limited tyramine potentiation; M30; MAO inhibition; Monoamine oxidase; Neurogenesis; Neuroprotection; Neurorestoration

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMITRIPTYLINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINESTERASE; ERYTHROPOIETIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HYPOXIA INDUCIBLE FACTOR; LADOSTIGIL; MOCLOBEMIDE; NEUROPROTECTIVE AGENT; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RASAGILINE; RIVASTIGMINE; SELEGILINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CELL CYCLE ARREST; DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

BDNF; GDNF; IRON CHELATOR; LADOSTIGIL; LIMITED TYRAMINE POTENTIATION; M30; MAO INHIBITION; MONOAMINE OXIDASE; NEUROGENESIS; NEUROPROTECTION; NEURORESTORATION;

ANIMALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 84887970188     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/S1353-8020(13)70032-4     Document Type: Article

References (30)

1. Pisani L, Catto M, Leonetti F, Nicolotti O, Stefanachi A, Campagna F, et al. Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases. Curr Med Chem 2011, 18:4568-4587.
2. Geldenhuys WJ, Van der Schyf CJ Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. Expert Opin Drug Discov 2013, 8:115-129.
3. Samadi A, de los Ríos C, Bolea I, Chioua M, Iriepa I, Moraleda I, et al. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur J Med Chem 2012, 52:251-262.
4. Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim MB Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal 2010, 13:919-949.
5. Weinreb O, Amit T, Bar-Am O, Youdim MB Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets 2012, 13:483-494.
6. Gallagher DA, Schrag A Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis 2012, 46:581-589.
7. Brichta L, Greengard P, Flajolet M Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems. Trends Neurosci 2013, 36:543-554.
8. Cassarino DS, Bennett JP An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Rev 1999, 29:1-25.
9. Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann N Y Acad Sci 1999, 893:154-175.
10. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative radioautography. Neuroscience 1994, 62:15-30.
11. Weinstock M, Bejar C, Wang RH, Poltyrev T, Gross A, Finberg JP, et al. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J Neural Transm 2000, 60(Suppl):157-169.
12. Gal S, Zheng H, Fridkin M, Youdim MB Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 2005, 95:79-88.
13. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 2005, 95:68-78.
14. Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 2007, 14:3835-3844.
15. Youdim MBH, Weinstock M Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug, TV3326 [(N-propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate]. Cell Mol Biol 2001, 21:555-573.
16. Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem 2007, 100:490-502.
17. Kupershmidt L, Weinreb O, Amit T, Mandel S, Bar-Am O, Youdim MB Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience 2011, 89:345-358.
18. Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Weinreb O The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid Redox Signal 2012, 17:860-877.
19. Kupershmidt L, Amit T, Bar-Am O, Weinreb O, Youdim MB Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice. Mol Neurobiol 2012, 46:217-220.
20. Gal S, Abassi ZA, Youdim MB Limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Neurotox Res 2010, 18:143-150.
21. Youdim MBH, Edmondson D, Tipton KF The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006, 7:295-309.
22. Sagi Y, Weinstock M, Youdim MB Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem 2003, 86:290-297.
23. Weinstock M, Gorodetsky E, Wang RH, Fross A, Weinreb O, Youdim MBH Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Neuropharmacology 2002, 43:999-1005.
24. O'Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 1983, 322:198-202.
25. Birkmayer W, Riederer P, Ambrozi L, Youdim MB Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet 1977, 1(8009):439-443.
26. Green AR, Mitchell BD, Tordoff AF, Youdim MB Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol 1977, 60(3):343-349.
27. Riederer P, Youdim MB Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 1986, 46(5):1359-1365.
28. Reynolds GP, Riederer P, Sandler M, Jellinger K, Seemann D Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J Neural Transm 1978, 43:271-277.
29. Gerlach M, Youdim MB, Riederer P Pharmacology of selegiline. Neurology 1996, 7(6 Suppl 3):S137-S145.
30. Weinstock M, Poltyrev T, Bejar C, Youdim MBH Effect of TV3326, a novel monoamine-oxidase-cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology 2002, 160:318-324.